Dr. Joseph Tam
Head, Obesity and Metabolism Laboratory, Director, Multidisciplinary Center on Cannabinoid Research
Received his B.Med.Sc., M.Sc., Ph.D. (Magna Cum Laude) and D.M.D. from the Hebrew University of Jerusalem. He did his postdoctoral training at the National Institutes of Health (NIH), and in 2011, he became a Staff Scientist at the NIH. In June 2014, Dr. Tam moved to the Hebrew University, where he won major national and international grants (ISF, GIF, EFSD, AbishFrankel, FPWR, TOS, and the prestigious European Research Council (ERC) Starting Grant). He authored over 23 peer-reviewed papers in leading journals (such as, Nature Medicine, Cell Metabolism, JCI, PNAS, Hepatology, Gastroenterology, The FASEB Journal, to name a few), and one book chapter in Hepatic de Novo Lipogenesis and Regulation of Metabolism. Dr. Tam’s research projects over the past fifteen years has crossed subjects, disciplines and methodologies, yet the main research interests remain focused on the different pathophysiological aspects of the endocannabinoid (eCB) system. Having a clinical background with basic science training, he has always been interested in how science can directly improve people’s everyday lives. Thus, he has strived unceasingly to integrate his clinical curiosity and experimental knowledge, in order to deepen the understanding of clinically relevant research questions. Dr. Tam is the head of the Obesity and Metabolism Laboratory at the Institute for Drug Research, where he focus on targeting the eCB system for Obesity, Diabetes and the metabolic syndrome. He also serves as a Director of the Hebrew University’s Multidisciplinary Center on Cannabinoid Research and a Scientific Advisory Board Member of Kalytera Therapeutics, Inc., which develops a portfolio of non-psychoactive cannabinoid and cannabinoid-modulating medicines for unmet market needs.